This section contains the latest highlighted research for patients from ASCO medical journals, including the Journal of Clinical Oncology, as well as an archive of research highlights from previous ASCO scientific meetings (2011-2015). For the latest research highlights from more recent ASCO meetings, visit the Cancer.Net Blog or check out Cancer.Net’s audio podcasts and videos for patients.
To search this archive, use the drop-down menu below. You can select a specific year, meeting or publication, and/or a specific topic, such as a type of cancer. Selecting "All" will take you to a complete list of articles that appear under all categories.
In a large, ongoing study, researchers found that a combination of ibrutinib (Imbruvica) and standard treatment slows the growth of chronic lymphocytic leukemia (CLL) and lowers patients’ risk of dying from the disease.
A recent study showed that the drug pacritinib works better for myelofibrosis than current treatments.
Early results from an ongoing study show that ibrutinib (Imbruvica) keeps relapsed chronic lymphocytic leukemia (CLL) from worsening for longer than ofatumumab (Arzerra), a standard treatment option for relapsed or refractory CLL.
In early, ongoing research, the drug, idelalisib helped to shrink tumors for patients with recurrent or treatment-resistant chronic lymphocytic leukemia (CLL). CLL is a slow-growing cancer and many patients do not need treatment until they start having symptoms. However, after treatment, most patients will have the disease come back, called recurrent or relapsed CLL. About 20% of patients will develop treatment-resistant or refractory CLL, meaning the disease comes back quickly or the original treatment did not work.
Most diffuse large B-cell lymphomas (DLBCL) that recur (come back after treatment) are found based on symptoms reported by patients, abnormal blood test results, or abnormal findings on a physical examination, rather than by a computed tomography (CT) scan, according to a recent study. DLBCL is the most common form of lymphoma and is typically curable. However, up to a third of patients will have the disease recur. A CT scan is a way to create pictures of the inside of the body and is currently recommended as a regular part of follow-up care for patients with DLBCL to watch for a recurrence.
In a new study on a type of leukemia called high-risk B-precursor acute lymphoblastic leukemia (ALL), researchers found that adolescents and young adults (ages 16 to 30) were more likely to have the disease recur (come back after treatment) and more likely to die from the disease than younger patients. Adolescents and young adults (often shortened to AYA) with cancer make up a unique group of patients with different medical, social, and emotional needs than both younger and older patients. The results of this study highlight the importance of finding new ways to treat leukemia and lower the side effects of treatment for these patients.
A new study shows that using high-dose methotrexate (multiple brand names) for children and young adults with a type of acute lymphoblastic leukemia (ALL) called high risk B-precursor ALL reduces the risk of recurrence when compared with the standard methotrexate regimen. Recurrence is when the ALL comes back after treatment.